Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171454501> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2171454501 endingPage "1875" @default.
- W2171454501 startingPage "1875" @default.
- W2171454501 abstract "Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma Zhengbo Song, Yiping Zhang Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China Purpose: This retrospective analysis evaluates the clinical efficacy and toxicity of second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). Methods: We retrospectively reviewed patients who had received second-line docetaxel-based chemotherapy for advanced ESCC in Zhejiang Cancer Hospital between January 2008 and December 2011. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis. Results: Eighty-five patients received docetaxel-based second-line chemotherapy after the failure of first-line fluorouracil-based treatment. Forty-four patients received docetaxel-platinum chemotherapy, and 41 received docetaxel single-agent treatment. The progression-free survival (PFS) and overall survival (OS) were 3.5 and 5.5 months in all of the patients, respectively. There were no statistically significant differences in PFS and OS between docetaxel-platinum and docetaxel single-agent chemotherapy groups (P-value 0.38 and 0.64, respectively). Response to first-line chemotherapy was a favorable prognostic factor for PFS in uni- and multivariate analyses (P-value 0.005 and 0.028, respectively). Conclusion: Patients with docetaxel-based second-line treatment obtained a moderate PFS advantage in advanced ESCC. Response to first-line chemotherapy was a favorable prognostic factor for PFS of second-line chemotherapy in advanced ESCC. Keywords: ESCC, efficacy, toxicity" @default.
- W2171454501 created "2016-06-24" @default.
- W2171454501 creator A5066879163 @default.
- W2171454501 creator A5085215477 @default.
- W2171454501 date "2014-10-01" @default.
- W2171454501 modified "2023-10-12" @default.
- W2171454501 title "Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma" @default.
- W2171454501 cites W108597970 @default.
- W2171454501 cites W1845207649 @default.
- W2171454501 cites W1970194999 @default.
- W2171454501 cites W1992033632 @default.
- W2171454501 cites W2003250903 @default.
- W2171454501 cites W2030270264 @default.
- W2171454501 cites W2035558101 @default.
- W2171454501 cites W2047106109 @default.
- W2171454501 cites W2111797676 @default.
- W2171454501 cites W2117799463 @default.
- W2171454501 cites W2132871418 @default.
- W2171454501 cites W2138098788 @default.
- W2171454501 cites W2154664762 @default.
- W2171454501 cites W2161817637 @default.
- W2171454501 cites W2170653176 @default.
- W2171454501 cites W3846700 @default.
- W2171454501 cites W80398914 @default.
- W2171454501 doi "https://doi.org/10.2147/ott.s66525" @default.
- W2171454501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4206393" @default.
- W2171454501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25342911" @default.
- W2171454501 hasPublicationYear "2014" @default.
- W2171454501 type Work @default.
- W2171454501 sameAs 2171454501 @default.
- W2171454501 citedByCount "12" @default.
- W2171454501 countsByYear W21714545012015 @default.
- W2171454501 countsByYear W21714545012016 @default.
- W2171454501 countsByYear W21714545012017 @default.
- W2171454501 countsByYear W21714545012021 @default.
- W2171454501 countsByYear W21714545012022 @default.
- W2171454501 crossrefType "journal-article" @default.
- W2171454501 hasAuthorship W2171454501A5066879163 @default.
- W2171454501 hasAuthorship W2171454501A5085215477 @default.
- W2171454501 hasBestOaLocation W21714545011 @default.
- W2171454501 hasConcept C121608353 @default.
- W2171454501 hasConcept C126322002 @default.
- W2171454501 hasConcept C143998085 @default.
- W2171454501 hasConcept C2776694085 @default.
- W2171454501 hasConcept C2780456651 @default.
- W2171454501 hasConcept C2781190966 @default.
- W2171454501 hasConcept C71924100 @default.
- W2171454501 hasConceptScore W2171454501C121608353 @default.
- W2171454501 hasConceptScore W2171454501C126322002 @default.
- W2171454501 hasConceptScore W2171454501C143998085 @default.
- W2171454501 hasConceptScore W2171454501C2776694085 @default.
- W2171454501 hasConceptScore W2171454501C2780456651 @default.
- W2171454501 hasConceptScore W2171454501C2781190966 @default.
- W2171454501 hasConceptScore W2171454501C71924100 @default.
- W2171454501 hasLocation W21714545011 @default.
- W2171454501 hasLocation W21714545012 @default.
- W2171454501 hasLocation W21714545013 @default.
- W2171454501 hasLocation W21714545014 @default.
- W2171454501 hasOpenAccess W2171454501 @default.
- W2171454501 hasPrimaryLocation W21714545011 @default.
- W2171454501 hasRelatedWork W13394025 @default.
- W2171454501 hasRelatedWork W1963691111 @default.
- W2171454501 hasRelatedWork W2080820783 @default.
- W2171454501 hasRelatedWork W2085307618 @default.
- W2171454501 hasRelatedWork W2087322859 @default.
- W2171454501 hasRelatedWork W2130974107 @default.
- W2171454501 hasRelatedWork W2167650070 @default.
- W2171454501 hasRelatedWork W2351661875 @default.
- W2171454501 hasRelatedWork W3032029751 @default.
- W2171454501 hasRelatedWork W4238574250 @default.
- W2171454501 isParatext "false" @default.
- W2171454501 isRetracted "false" @default.
- W2171454501 magId "2171454501" @default.
- W2171454501 workType "article" @default.